SCP
MREO

Sender Company & Partners’s Mereo BioPharma MREO Stock Holding History

Sender Company & Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-333,904
Closed -$534K – 79
2021
Q4 		$534K Buy
+333,904
New +$668K 0.27% 72

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Sender Company & Partners's MREO Position: Q1 2022 in Review

Sender Company & Partners sold out of Mereo BioPharma (MREO) in Q1 2022, closing a stake of 333,904 shares — an estimated $534K sold.

Sender Company & Partners first reported a position in MREO in Q4 2021 and held it in 1 quarter. The position peaked at $534K in Q4 2021. 60 funds tracked by Wall St. Rank hold MREO as of Q1 2022.

  • Sender Company & Partners reported no remaining Mereo BioPharma position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 333,904 Mereo BioPharma shares in Q1 2022, an estimated $534K.
  • Sender Company & Partners first reported a position in Mereo BioPharma in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Mereo BioPharma position peaked at $534K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.